Shopping Cart 0
Cart Subtotal
USD 0

Avadel Pharmaceuticals Plc (AVDL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Avadel Pharmaceuticals Plc (Avadel), formerly Flamel Technologies SA is a specialty pharmaceutical company, which develops and commercializes drugs for allergy, asthma, central nervous system (CNS) (narcolepsy), pain, respiratory diseases and diabetes. The company's products are built on its proprietary polymer-based technologies: Micropump, an oral sustained release microparticles platform, LiquiTime, a Micropump-derived platform for liquid oral products, Trigger Lock, a Micropump-derived platform that enables abuse-resistant modified and controlled release formulations and Medusa that enables controlled release of injectables. It sells its products in the US, France, and Ireland. The company operates in St. Louis, Missouri, and Charlotte in the US. Avadel is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals Plc (AVDL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Avadel Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 11

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Flamel Technologies Enters Into Product Partnership Agreement With Pharma Company 13

Merger 14

Flamel Technologies Merges with Avadel Pharma 14

Licensing Agreements 15

Cerecor to Enter into Licensing Agreement with Avadel Ireland 15

Avadel Pharma to Enter into Licensing Agreement with Serenity Pharma for Noctiva 16

Perrigo Enters into Licensing Agreement with Flamel Ireland 18

Tris Pharma And FSC Labs Enter Into Licensing Agreement For Karbinal ER 19

Equity Offering 20

Flamel to Raise USD13.1 Million in Private Placement of Shares 20

Flamel Technologies Completes Public Offering Of Shares For USD 121 Million 21

Debt Offering 23

Avadel Pharma Raises USD143.8 Million in Private Placement of 4.5% Notes Due 2023 23

Flamel Technologies Completes Private Placement Of Notes Due 2017 For USD 15 Million 24

Asset Transactions 25

Cerecor Acquires Pediatric Business from Avadel Pharma 25

Aytu BioScience Acquires Rights to Primsol from FSC Labs for USD1.8 Million 27

Recipharm Acquires Development and Manufacturing Facility from Flamel for USD13.2 Million 28

Acquisition 30

Flamel Technologies Acquires FSC Holdings 30

Flamel Technologies Acquires Eclat Pharma For USD 12 Million 32

Avadel Pharmaceuticals Plc-Key Competitors 34

Avadel Pharmaceuticals Plc-Key Employees 35

Avadel Pharmaceuticals Plc-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Recent Developments 38

Financial Announcements 38

Nov 05, 2018: Avadel Pharmaceuticals reports third quarter 2018 financial results 38

Aug 07, 2018: Avadel Pharmaceuticals reports second quarter 2018 financial results 40

May 02, 2018: Avadel Pharmaceuticals Reports First Quarter 2018 Results 42

Mar 08, 2018: Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Results 44

Nov 08, 2017: Avadel Pharmaceuticals Reports Third Quarter 2017 Results 45

Aug 08, 2017: Avadel Pharmaceuticals Reports Second Quarter 2017 Results 47

May 09, 2017: Avadel Pharmaceuticals Reports First Quarter 2017 Results 49

Mar 07, 2017: Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Results 50

Corporate Communications 52

Mar 22, 2018: Avadel Pharmaceuticals Announces Promotion of Gregory J. Divis to Chief Operating Officer 52

Mar 30, 2017: Avadel Pharmaceuticals Announces Planned Reduction of French Workforce 53

Jan 03, 2017: Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Commercial Officer 54

Clinical Trials 55

May 17, 2017: Avadel Pharmaceuticals Supports the Narcolepsy Network's 5th Annual DREAM BIG Walk 55

Other Significant Developments 56

Dec 29, 2017: Avadel Pharmaceuticals Issues 2018 Corporate Outlook 56

Jan 05, 2017: Avadel Pharmaceuticals Provides 2017 Guidance and Business Update 58

Appendix 60

Methodology 60

About GlobalData 60

Contact Us 60

Disclaimer 60


List Of Figure

List of Figures

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Avadel Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Avadel Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Avadel Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 11

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Flamel Technologies Enters Into Product Partnership Agreement With Pharma Company 13

Flamel Technologies Merges with Avadel Pharma 14

Cerecor to Enter into Licensing Agreement with Avadel Ireland 15

Avadel Pharma to Enter into Licensing Agreement with Serenity Pharma for Noctiva 16

Perrigo Enters into Licensing Agreement with Flamel Ireland 18

Tris Pharma And FSC Labs Enter Into Licensing Agreement For Karbinal ER 19

Flamel to Raise USD13.1 Million in Private Placement of Shares 20

Flamel Technologies Completes Public Offering Of Shares For USD 121 Million 21

Avadel Pharma Raises USD143.8 Million in Private Placement of 4.5% Notes Due 2023 23

Flamel Technologies Completes Private Placement Of Notes Due 2017 For USD 15 Million 24

Cerecor Acquires Pediatric Business from Avadel Pharma 25

Aytu BioScience Acquires Rights to Primsol from FSC Labs for USD1.8 Million 27

Recipharm Acquires Development and Manufacturing Facility from Flamel for USD13.2 Million 28

Flamel Technologies Acquires FSC Holdings 30

Flamel Technologies Acquires Eclat Pharma For USD 12 Million 32

Avadel Pharmaceuticals Plc, Key Competitors 34

Avadel Pharmaceuticals Plc, Key Employees 35

Avadel Pharmaceuticals Plc, Subsidiaries 36

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Avadel Pharmaceuticals Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Avadel Pharmaceuticals Plc (Avadel), formerly Flamel Technologies SA is a specialty pharmaceutical company, which develops and commercializes drugs for allergy, asthma, central nervous system (CNS) (narcolepsy), pain, respiratory diseases and diabetes. The company's products are built on its proprietary polymer-based technologies: Micropump, an oral sustained release microparticles platform, LiquiTime, a Micropump-derived platform for liquid oral products, Trigger Lock, a Micropump-derived platform that enables abuse-resistant modified and controlled release formulations and Medusa that enables controlled release of injectables. It sells its products in the US, France, and Ireland. The company operates in St. Louis, Missouri, and Charlotte in the US. Avadel is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals Plc (AVDL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Avadel Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 11

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Flamel Technologies Enters Into Product Partnership Agreement With Pharma Company 13

Merger 14

Flamel Technologies Merges with Avadel Pharma 14

Licensing Agreements 15

Cerecor to Enter into Licensing Agreement with Avadel Ireland 15

Avadel Pharma to Enter into Licensing Agreement with Serenity Pharma for Noctiva 16

Perrigo Enters into Licensing Agreement with Flamel Ireland 18

Tris Pharma And FSC Labs Enter Into Licensing Agreement For Karbinal ER 19

Equity Offering 20

Flamel to Raise USD13.1 Million in Private Placement of Shares 20

Flamel Technologies Completes Public Offering Of Shares For USD 121 Million 21

Debt Offering 23

Avadel Pharma Raises USD143.8 Million in Private Placement of 4.5% Notes Due 2023 23

Flamel Technologies Completes Private Placement Of Notes Due 2017 For USD 15 Million 24

Asset Transactions 25

Cerecor Acquires Pediatric Business from Avadel Pharma 25

Aytu BioScience Acquires Rights to Primsol from FSC Labs for USD1.8 Million 27

Recipharm Acquires Development and Manufacturing Facility from Flamel for USD13.2 Million 28

Acquisition 30

Flamel Technologies Acquires FSC Holdings 30

Flamel Technologies Acquires Eclat Pharma For USD 12 Million 32

Avadel Pharmaceuticals Plc-Key Competitors 34

Avadel Pharmaceuticals Plc-Key Employees 35

Avadel Pharmaceuticals Plc-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Recent Developments 38

Financial Announcements 38

Nov 05, 2018: Avadel Pharmaceuticals reports third quarter 2018 financial results 38

Aug 07, 2018: Avadel Pharmaceuticals reports second quarter 2018 financial results 40

May 02, 2018: Avadel Pharmaceuticals Reports First Quarter 2018 Results 42

Mar 08, 2018: Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Results 44

Nov 08, 2017: Avadel Pharmaceuticals Reports Third Quarter 2017 Results 45

Aug 08, 2017: Avadel Pharmaceuticals Reports Second Quarter 2017 Results 47

May 09, 2017: Avadel Pharmaceuticals Reports First Quarter 2017 Results 49

Mar 07, 2017: Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Results 50

Corporate Communications 52

Mar 22, 2018: Avadel Pharmaceuticals Announces Promotion of Gregory J. Divis to Chief Operating Officer 52

Mar 30, 2017: Avadel Pharmaceuticals Announces Planned Reduction of French Workforce 53

Jan 03, 2017: Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Commercial Officer 54

Clinical Trials 55

May 17, 2017: Avadel Pharmaceuticals Supports the Narcolepsy Network's 5th Annual DREAM BIG Walk 55

Other Significant Developments 56

Dec 29, 2017: Avadel Pharmaceuticals Issues 2018 Corporate Outlook 56

Jan 05, 2017: Avadel Pharmaceuticals Provides 2017 Guidance and Business Update 58

Appendix 60

Methodology 60

About GlobalData 60

Contact Us 60

Disclaimer 60


List Of Figure

List of Figures

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Avadel Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Avadel Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Avadel Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 11

Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Flamel Technologies Enters Into Product Partnership Agreement With Pharma Company 13

Flamel Technologies Merges with Avadel Pharma 14

Cerecor to Enter into Licensing Agreement with Avadel Ireland 15

Avadel Pharma to Enter into Licensing Agreement with Serenity Pharma for Noctiva 16

Perrigo Enters into Licensing Agreement with Flamel Ireland 18

Tris Pharma And FSC Labs Enter Into Licensing Agreement For Karbinal ER 19

Flamel to Raise USD13.1 Million in Private Placement of Shares 20

Flamel Technologies Completes Public Offering Of Shares For USD 121 Million 21

Avadel Pharma Raises USD143.8 Million in Private Placement of 4.5% Notes Due 2023 23

Flamel Technologies Completes Private Placement Of Notes Due 2017 For USD 15 Million 24

Cerecor Acquires Pediatric Business from Avadel Pharma 25

Aytu BioScience Acquires Rights to Primsol from FSC Labs for USD1.8 Million 27

Recipharm Acquires Development and Manufacturing Facility from Flamel for USD13.2 Million 28

Flamel Technologies Acquires FSC Holdings 30

Flamel Technologies Acquires Eclat Pharma For USD 12 Million 32

Avadel Pharmaceuticals Plc, Key Competitors 34

Avadel Pharmaceuticals Plc, Key Employees 35

Avadel Pharmaceuticals Plc, Subsidiaries 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Avadel Pharmaceuticals Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.